Home
About Optovent AB
Products and pipeline
Technology
Primary applications
Press
Contact
RHCC 

ProtR-C is a drug delivery vehicle developed from a platform based on the RHCC fragment of the tetrabrachion protein complex of Staphylothermus marinus (S.marinus). S.marinus is an archaebacterium isolated from the black smokers of the East Pacific Rise. The RHCC protein fragment is small; about 7.5 x 2.5 nm2, rod shaped, and has interior hydrophobic cavities. A range of metal complexes bind stably to the interior cavities, and this property is taken advantage of when developing RHCC for drug delivery.

The RHCC is

     • Extremely stable
     • Easy to produce in large quantities
     • Ideally sized for a carrier

The RHCC as a drug carrier

     • Increases efficacy
     • Reduces side-effects
     • Expands indications

The product developed is:

ProtR-C: The RHCC loaded with cisplatin for drug delivery to tumor by EPR or targeting effect.

Partners in development of the RHCC technology platform are Karolinska Institute, Uppsala University, Linköping University, and Heidelberg University.  

 
Optovent AB  Box 1224  SE-581 12  Linköping  Sweden  Telephone: +46 8 663 5700